WO2002055081A2 - Use of chelators in the treatment of macular degenerative disease - Google Patents
Use of chelators in the treatment of macular degenerative disease Download PDFInfo
- Publication number
- WO2002055081A2 WO2002055081A2 PCT/IB2001/002265 IB0102265W WO02055081A2 WO 2002055081 A2 WO2002055081 A2 WO 2002055081A2 IB 0102265 W IB0102265 W IB 0102265W WO 02055081 A2 WO02055081 A2 WO 02055081A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clioquinol
- phanquinone
- use according
- amount
- mmps
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the present invention relates to the use of a combination of two known compounds used together or each one of these two compounds used separately for the manufacture of a pharmaceutical composition for the prevention and treatment of macular degeneration. Further the invention relates a pharmaceutical composition for such prevention and treatment. The invention is also directed to methods of prevention or treatment of macular diseases related to impaired extracellular matrix degradation.
- Age-related macular degeneration is a leading cause of visual loss. It is an eye disease that is present (at least to some degree) in millions of older persons. Early diagnosis of age-related macular degeneration is essential to successful treatment. Age-related macular degeneration affects the macula, a small portion of the retina. The retina is the light-sensing nerve tissue that lines the inside of the eye. All parts of the retina contribute to sight, but only the macula can provide the sharp, straight-ahead vision that is needed for driving and reading small print.
- AMD does not develop until a person is 65 or older. A few people in their 40s and 50s, however, may be affected by AMD. Most patients with AMD have a form of the disease that develops very slowly. It is called the atrophic or "dry" form. In it, tiny yellowish deposits called drusen develop beneath the macula. Also, the layer of light-sensitive cells in the macula becomes thinner as some cells break down. These changes typically cause a dimming or distortion of vision that people find most noticeable when they try to read. Generally, if one eye has dry AMD, the other eye will also have some signs of the condition. Thus the person with dry AMD may eventually have visual problems in both eyes. However, the dry form of AMD rarely causes total loss of reading vision.
- NEI laser photo-coagulation is of value only to the relatively few people who have the neovascular form of AMD, with new blood vessels actively growing in the macula and threatening to cause serious vision loss.
- laser treatment is of any value for people with the dry form of AMD. Because the laser cannot restore vision already lost from AMD, an eye whose macula has been badly damaged by this disease would not benefit from laser treatment, NEI reports. It important for AMD, and neovascular AMD in particular, should be detected as early as possible.
- Drusen and the other macular changes typical of the atrophic type of AMD cannot be seen by the person who has them, but are visible to an eye care specialist examining the eye. Individuals who are middle-aged or older are advised to visit an eye care specialist regularly to be checked for early signs of
- AMD AMD, glaucoma, and other eye diseases that are linked to ageing.
- AMD AMD is a leading cause of visual loss in the USA. It is an eye disease that is present (at least to some degree) in millions of older Americans. Early diagnosis of age-related macular degeneration is essential to successful treatment. Age-related macular degeneration, affects the macula, a small portion of the retina. The retina is the light-sensing nerve tissue that lines the inside of the eye. All parts of the retina contribute to sight, but only the macula can provide the sharp, straight-ahead vision that is needed for driving and reading small print.
- a person's chances of developing AMD are greater than average if he or she has a near relative with the disease. Medical science does not yet know what other factors may contribute to an individual's likelihood of experiencing
- Laser treatment is performed by a specially trained ophthalmologist in his office or in an eye clinic at a medical centre.
- a local anaesthetic may be used to prevent discomfort during the laser treatment session.
- the session generally takes only a few minutes.
- the individual is able to return home and continue his or her normal activities.
- the individuals usually will be asked to return to the doctor's office for follow-up appointments. If additional growth of new blood vessels is found, further laser treatment may be indicated.
- the individuals can use the home test described above to detect any visual changes that might signal renewed blood vessel growth. At present, there is no proven method of preventing dry AMD or the onset of the neovascular form of the disease.
- Called low vision aids these devices have special lenses or electronic systems that produce enlarged images of nearby objects. If you need low vision aids, your eye care specialist can generally prescribe them. Often, he or she will be able to suggest further sources you might contact to get information about counseling, training and other special services for people with low vision. Generally, when dry AMD is found, the individual is encouraged to return for further check-ups. Also, he or she may seek to perform a simple, at-home test for visual changes. The test involves looking at a piece of paper marked with a grid of straight lines.
- MMPs matrix metalloproteinases
- the enzymes are initially expressed as inactive pro-enzymes becoming activated by proteolytic cleavage of their amino termini.
- the MMPs play a key role in the normal physiology of connective tissue development, morphogenesis and wound healing but their unregulated activity is believed to be implicated in numerous disease processes including arthritis, tumour cell metastases and atherosclerotic disease.
- Xilinas M. (PCT/IB01/00715 and PCT/IB01/00712) has presented an invention related to a new use of the known compounds phanquinone and clioquinol respectively, that pertains to their use for the manufacture of pharmaceutical compositions for the treatment or prevention of pathological conditions influenced by the action of MMPs.
- a method for the treatment of a subject having or suspected of having a pathological condition influenced by the action of MMPs in the development of macular degenerative disease including age-related macular degeneration.
- the activity of clioquinol and/or phanquinone is centred on the chelation of zinc in the eye that will restrict the different MMPs involved in the development of the macular diseases from their action on the extracellular matrix ECM.
- phanquinone and clioquinol have an inhibiting action on the enzymes.
- MMPs tissue inhibitors of metalloproteinases
- TIMPs tissue inhibitors of metalloproteinases
- ECM extracellular matrix
- the TIMPs form high affinity 1 :1 complexes with the active forms of most MMPs but show varies specificity for different pro-MMPs allowing TIMPs to control the activation of specific MMPs. Activities have also been ascribed to the
- TIMPs that are independent of their ability to inhibit MMPs.
- MMPs have been shown to be associated with diseases involving neovascularisation and abnormal cellular migration or proliferation. A number of diseases of this type affect the retina (Plantner et al, 1998, Exp Eye Res, 67: 637- 45). In the interphoto receptor matrix and the vitreous the most abundant metalloproteinase is the MMP-2. The level of MMP-2 is nearly double specifically in retinal pigment epithelium associated in the interphoto receptor matrix from eyes of patients with age related macular degeneration. It is concluded that the changes occurring in these patients and especially the neovascularisation which accompanies the exudative form is associated with the MMP-2 higher levels.
- the MMPs play a key role in the normal physiology of connective (Brew et al, Biochem Biophys Acta, 2000, 1477:267-83).
- An important mechanism for the regulation of the activity of MMPs is via binding to a family of homologous proteins (TIMP-1 to TIMP-4).
- the two-domain TIMPs are of relatively small size, yet have been found to exhibit several biochemical and physiological/biological functions, including inhibition of active MMPs, proMMP activation, cell growth promotion, matrix binding, inhibition of angiogenesis and the induction of apoptosis. Mutations in TIMP-3 are the cause of Sorsby's fundus dystrophy in humans, a disease that results in early onset macular degeneration.
- TIMPs have been elucidated and their complexes with metalloproteinases, and the results of mutational and other studies of structure-function relationships that have enhanced our understanding of the mechanism and specificity of the inhibition of MMPs by TIMPs.
- MMP-2 the most abundant MMP interphoto receptor matrix and vitreous, was measured with respect to age in normal human donor eyes and compared to donors with age-related macular degeneration. The level of MMP-2, was nearly doubled specifically in retinal pigment epithelium-associated interphoto receptor matrix from eyes with age- related macular degeneration, suggesting that MMP-2 may be associated with the changes that occur in age-related macular degeneration, especially the neovascularisation which accompanies the exudative form of the disease.
- MMPs are associated with neovascularisation and in particular MMP-7 was expressed in Bruch membrane of choroidal neovascular membranes in age- related macular degeneration. MMP-7 may be an important factor for the development of the sub-macular neovascular membrane in age-related macular degeneration.
- TIMP-3 neurodegenerative retinal disease
- the level of mRNA coding for TIMP-3 is increased in retinas affected by the photoreceptor degenerative disease, simplex retinitis pigmentosa, and mutations in TIMP-3 are associated with an inherited form of macular dystrophy.
- Immunoreactive TIMP-3 is present in normal retinal pigment epithelium, and in degenerative retinas particularly at Bruch's membrane and additionally in photoreceptor-retaining regions in simplex RP. The pattern suggests a role for TIMP-3 in normal retinal homeostasis, and, in the disease state, in the modulation of extracellular matrix metabolism and neovascularisation.
- Matrix metalloproteinases and metalloproteinase inhibitors are present in human interphoto receptor matrix and vitreous (Plantner et al, Curr Eye Res, 1998, 17:132-40) and it was established that MMPs and TIMPs were present in human interphoto receptor matrix, and vitreous. It was demonstrated that it is most likely that MMPs and TIMPs are involved in normal turnover within the ECM that surround the neural retina and play a role in a number of retinal diseases, particularly proliferative diabetic retinopathy and age-related macular degeneration.
- TIMP-3 is not a major factor in the cause of age related macular degeneration, adult vitelliform macular dystrophy, central areolar choroidal dystrophy, syndrome-associated macular dystrophies, cone-rod dystrophy, and in a group with unspecified macular degeneration and that only Sorsby's fundus dystrophy appears to be only associated with mutations in TIMP3.
- TIMPs play a crucial role in the physiological turnover of ECM by tightly regulating MMPs activities. Disturbances in the TIMP/MMP system have been implicated in many disease processes where loss of ECM integrity is a principal feature. More recently, it has been shown that mutations in TIMP3 cause the autosomal dominant disorder Sorsby's fundus dystrophy, in which condition characteristic ECM irregularities occur in Bruch's membrane.
- MMP-2 and MMP-9 have shown that MMP-2 and MMP-9 play possible role in choroidal neovascularisation and support their role in the development of choroidal neovascularisation in macular degeneration.
- MMP-2 and MMP-9 have shown that MMP-2 and MMP-9 play possible role in choroidal neovascularisation and support their role in the development of choroidal neovascularisation in macular degeneration.
- the localisation of MMP-2 and MMP-9 to the areas of new vessel formation and to the enveloping Bruch's-like membrane, respectively, suggests that MMP-2 and
- MMP-9 may be co-operatively involved in the progressive growth of choroidal neovascular membranes in macular disease.
- TIMP-3 Changes of TIMP-3 in Bruch's membrane occur during ageing and in age-related macular degeneration (Kamei and Hollyfield Invest Ophthalmoi Vis Sci, 1999, 40:2367-75). TIMP-3 is present uniformly across Bruch's membrane in the normal samples. In samples from donors more than 50 years of age, immunostaining was intense and TIMP-3 increased with age. In macular degeneration eyes, TIMP-3 distribution in Bruch's membrane is abundant in areas of continuous soft drusen but absent in areas below the retinal pigment epithelium. During normal ageing, TIMP-3 content in Bruch's membrane of the macula shows a significant increase. TIMP-3 content in age related macular degeneration eyes Ms elevated relative to that of age-matched normal eyes. Higher levels of TIMP-3 may contribute to the thickening of Bruch's membrane observed in macular disease.
- Brown PD (Expert Opin Investig Drugs 2000 Sep;9(9):2167-77) reported recently synthetic, potent, low molecular weight MMP inhibitors have been developed and, over the past five years and that these agents have begun clinical testing in patients with cancer, rheumatoid arthritis, osteoarthritis and acute macular degeneration
- the new use of clioquinol and/or phanquinone for the manufacture of a pharmaceutical composition for the treatment or prevention of pathological conditions influenced by the action of MMPs in eye macular disease is provided.
- clioquinol inhibits the metalloproteinases-1 (MMP-1 ) at concentrations of 10 microM.
- MMP-1 metalloproteinases-1
- the inhibitory effect of clioquinol is increasing by increasing the concentration of the drug from 0.1 to 1 and further to lOmicroM.
- the clioquinol concentration was increase to 100 microM the inhibition of the MMP-1 was practically total.
- clioquinol was found to inhibit biochemical activity of MMP-2, MMP-3, MMP-7 and MMP-9 in an increasing manner proportionally to the clioquinol concentration (0.1 , 1 , 10 and lOOmicroM).
- Phanquinone shares with clioquinol a similar chelating activity towards zinc. Both molecules are also chelating copper and other metals.
- the inhibitory activity of phanquinone as to the MMPs is postulated to be similar to that shown already experimentally for clioquinol.
- Ointment and eye drop preparations of clioquinol and phanquinone in suitable vehicles can achieve local concentrations in the eye of 100 microM that will be sufficient to inhibit in the macular tissues the metalloproteinases activity and override their deleterious degenerative effects.
- Various diseases are influenced by MMPs. Examples of such diseases are age related macular degeneration as well as tumour metastasis and angiogenesis, rheumatoid arthritis, corneal ulceration, osteoporosis and osteoarthritis, multiple sclerosis, diabetic complications, periodontal disease and atherosclerosis.
- the common feature for the pathological conditions which may be influenced by MMPs is that such conditions involve tissue breakdown.
- the cause of the diseases influenced by MMPs is due to an over expression and over-activity of the MMPs leading to increased degradation of tissue.
- Clioquinol and phanquinone separately or in combination are two molecules intended to be used for the prevention or treatment of macular degenerative disease. Achieving concentrations by local eye administration as an ointment or as eye drops preferably, at concentrations preferably of 1% of either clioquinol and/or phanquinone will be sufficient based on our MMP studies of clioquinol, to modulate the effect of the MMPs by decreasing them and reestablish a balance between the MMP and corresponding TIMP activity, Using such formulation concentrations inhibition of MMPs can be achieved as necessary ( of the order of 100 microM ).
- clioquinol and/or phanquinone can by maintained as long as required therapeutically for periods ranging from three weeks up to several years or decades. Such effects will act both in a therapeutic as well as prophylactic manner as clinically required.
- Alzheimer's disease due to their ability to chelate zinc and copper and to reduce oxidative reactions in the brain.
- Amyloid in Alzheimer's disease is aggregated in the presence of mainly zinc but also copper and clioquinol and phanquinone are used to chelate the two metals in the brain and block the aggregation of amyloid and the formation of plaques.
- Clioquinol or phanquinone or their combination are therefore indicated for the treatment of macular diseases, including age related macular degeneration.
- the treatment is directed whenever there is an over expression or over-activity of one or more of the MMPs that results in pathological conditions and vitro-retinal disease.
- the treatment is indicated for neuro-degenerative retinal diseases, including exudative and atrophic age related macular degeneration as well as for photoreceptor degenerative disease, simplex retinitis, proliferative diabetic retinopathy, Sorsby's fundus dystrophy, macular hole, presumed ocular histoplasmosis syndrome, proliferative diabetic retinopathy, epiretinal membrane, vitreo-macular traction syndrome, macro-aneurysm with subretinal haemorrhage, central retinal vein occlusion with vitreous haemorrhage and proliferative vitreoretinopathy or in any other vitro-retinal condition clioquinol and/or phanquinone will modulate and re-establish the equilibrium between the enzymatic activity of the respective MMPs
- Clioquinol (iodo- chlorohydroxyquinol, iodo- chloro hydroxyquinoline, chloro- iodoquine, 7-iodo -5-chloro-8 -hydroxyquinoline, 5-Chloro- 7-iodo -8- hydroxy quinoline, 5-Chloro-7-iodo-8-quinolinol, 5-Chloro- 8-hydroxy- 7- iodoquinoline) is a known antiamoebic and antibacterial drug that has been used extensively as such in the past and sold by CIBA-GEIGY as
- Phanquinone (4J-phenanthroline-5,6-dione) has hitherto been used for the treatment of parasites and in particular giardia and amoebas. Phanquinone has been sold by CIBA-GEIGY under the trademark ENTOBEX. Phanquinone has received renewed interest in recent years and we have suggested it for the treatment of Alzheimer's disease (WO 99/09981). Phanquinone has a large number of clinical investigations completed in the past where it has shown a good safety profile when given orally in the treatment of parasitic disease and has shown no toxic effects when used at dosages up to 150mg daily for periods ranging from three weeks to six months.
- Clioquinol is a chelating agent with proven activity as to the sequestration by chelation of metals including zinc, iron, manganese, copper, mercury, nickel, copper and cobalt. Injectable preparations of clioquinol have been reported as well penetrating in the brain and crossing the blood brain barrier and achieving concentrations in the brain of the order of 20microg/ml. The concentration of clioquinol was also found to be high in areas of the brain like the hippocampus that are directly involved in Alzheimer's disease.
- clioquinol has the ability to chelate several heavy metals in vivo and in the brain and in particular zinc and copper.
- Phanquinone has the ability to chelate copper as well as zinc in the brain.
- the ability of copper chelation is three times more pronounced with phanquinone compared to clioquinol.
- clioquinol has a two fold at least more pronounced ability to chelate zinc in comparison to phanquinone.
- phanquinone possesses the same beneficial properties as clioquinol as to the abolishment of the amyloid formation and the resolubilisation of amyloid in the brain.
- Clioquinol has been given in the past at dosages of 250mg three times daily for periods of up to three months for the treatment of intestinal amoebiasis. It has been also used extensively in the treatment of intestinal infectious diarrhoea. The only reported toxicity with clioquinol was the one reported in Japan when excessive dosages were given and for long periods of time reaching up to two years. Then a neurotoxicity called sub-acute myelo optic neurotoxicity (SMON) was developed. In recent research it has been shown that this toxicity is related to the vitamin B 12 metabolism.
- SMON sub-acute myelo optic neurotoxicity
- clioquinol will chelate zinc and other heavy metals in the brain and in specific brain and due to its lipophilicity is well absorbed per os achieving high cerebrospinal fluid and brain concentrations.
- a ⁇ amyloid A ⁇ amyloid
- a ⁇ is a normal component of biological fluids whose function is unknown. A ⁇ accumulates in a number of morphologies varying from highly insoluble amyloid to deposits that can be extracted from post-mortem tissue in aqueous buffer. The factors behind the accumulation are unknown, but we have systematically appraised the solubility of synthetic A ⁇ peptide in order to get some clues as to what kind of pathological environment could induce the peptide to precipitate.
- a ⁇ has three principal vulnerabilities- zinc, copper and low pH (Bush,
- a mild treatment with chelating agents allows rapid resolubilisation of the aggregated A ⁇ .
- Abundant ephemeral deposits of this type may be present at all times in both affected the unaffected individuals but may only be detectable as background staining by immunohistology.
- the results suggest that metal chelators will have a therapeutic use in AD and serve a prophylactic function in reducing amyloid burden in the clinical state.
- Clioquinol is the only chelator that enriched in the brain due to its hydrophobicity, making it an excellent candidate for development towards clinical trials.
- Phanquinone has been used extensively in the past for the treatment of parasitic disease and specifically in the treatment of giardiasis. It has been also used in combination with clioquinol in different concentrations for the same indications as clioquinol. Recently we have undertaken extensive research for using phanquinone in the treatment of Alzheimer's disease. From experimental data it has been shown that phanquinone has the ability to chelate copper as well as zinc in the brain. The ability of copper chelation is three times more pronounced with phanquinone compared to clioquinol. It has also been shown that phanquinone possesses the same beneficial properties as clioquinol as to the abolishment of the amyloid formation and the resolubilisation of amyloid in the brain.
- MMPs are directly involved in macular degenerative disease in man.
- the pharmaceutical composition manufactured using clioquinol and/or phanquinone preferably comprises one or more pharmaceutical acceptable carriers and, optionally, one or more further active constituent(s).
- the carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
- the clioquinol and/or phanquinone and optionally, further active constituents in the pharmaceutical composition are purified.
- the amount of clioquinol and/or phanquinone and, optionally, further active constituents required for said treatment or prevention will vary according to the route of administration, the disorder to be treated, the condition, age, the file history of the subject, and the galenic formulation of the pharmaceutical composition etc.
- the amount of phanquinone and of clioquinol is preferably effective to provide for at least a partially inhibition of at least one of the enzymes belonging to the group of MMPs.
- a suitable therapeutically effective amount of phanquinone and/or of clioquinol in the oral pharmaceutical composition is, for example 1 mg to 1 g, preferably 10 mg to 50 mg of phanquinone and/or 1 mg to 1 g of clioquinol, preferably 20 mg to 250 mg.
- the amount given is preferably the amount necessary to inhibit any detrimental effects of clioquinol administration and 5 micro g to 2 mg.
- the effective concentration is, for example 0.1 to 3 % of phanquinone and/or of clioquinol.
- the actually administered amounts of phanquinone and/or clioquinol, and optionally further active constituents, such as vitamin B 12 may be decided by a supervising physician. If the pharmaceutical composition in addition to clioquinol and/or phanquinone comprises further active constituents they may be in the same composition for administering in combination concurrently, or in different compositions for administering substantially simultaneously but separately, or sequentially, the further active ingredients may be administered prior or subsequently to the administering of phanquinone and/or clioquinol.
- compositions include those suitable for parenteral
- the pharmaceutical composition may be formulated as tablets, pills, syrups, capsules, suppositories, formulations for transdermal application, powders, especially lyophilised powders for reconstitution with a carrier for intravenous administration, eye ointments, eye drops, eye solutions for eye injection.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapy is administered.
- the carriers in the pharmaceutical composition may comprise a binder, such as microcrystalline cellulose, polivinylpyrrolidone (polyvidone or povidone), polysorbate 80, polyethylene glycol (Macrogol), gum, tragacanth, gelatine, starch, lactose, or lactose monohydrate; a disintegrating agent, such as alginic acid, maize starch and the like; a lubricant or surfactant, such as magnesium stearate, or sodium, lauryl sulfate; a glidant, such as colloidal silicon dioxide; a sweetening agent, such as sucrose or saccharin; and/or a flavouring agent, such as peppermint, methyl salicylate, orange flavouring.
- a binder such as microcrystalline cellulose, polivinylpyrrolidone (polyvidone or povidone), polysorbate 80, polyethylene glycol (Macrogol), gum, tragacanth, gelatine, starch,
- compositions suitable for oral administration may be obtained by compression or moulding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by mixing the constituent(s), and compressing the mixture obtained in a suitable apparatus into tablets having suitable size.
- the clioquinol and/or phanquinone may be mixed with a binder, a lubricant, an inert diluent and/or a disintegrating agent and the further optionally present constituents may be mixed with a diluent, a lubricant and/or a surfactant.
- free-flowing clioquinol and/or phanquinone powder is mixed in a binder, such as microcrystalline cellulose, and a surfactant, such as lauryl sulphate, until a homogeneous mixture is obtained.
- a binder such as microcrystalline cellulose
- a surfactant such as lauryl sulphate
- another binder such as polyvidone
- Said mixture is passed through granulating sieves and dried by desiccation before being compressed into tablets in a standard compressing apparatus.
- free-flowing clioquinol and/or phanquinone powder is mixed with surfactants and/or emulsifying agents, such as Sapamine (N-(4'-stearoyl amino phenyl)-trimethylammonium methyl sulphuric acid) and lactose monohydrate until a uniform distribution of the constituents is obtained.
- a second preparation containing a disintegrating agent, such as maize starch is added to the clioquinol and/or phanquinone mixture while being continuously stirred.
- Such a second preparation may be prepared by adding excess boiling water to a maize starch suspended in cold water. The final mixture is granulated and dried as above and mixed with maize starch and magnesium stearate and finally compressed into tablets in a standard apparatus.
- a tablet may be coated or uncoated.
- An uncoated tablet may be scored.
- a coated tablet may be coated with sugar, shellac, film or other enteric coating agents.
- compositions suitable for parenteral administration include sterile solutions or suspensions of the above constituents.
- An aqueous or oily carrier may be used.
- Such pharmaceutical carriers may be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- Formulations for parenteral administration also include a lyophilised powder comprising clioquinol and/or phanquinone and, optionally an aqueous solution of carboxymethylcellulose and lauryl sulphate.
- the pharmaceutical formulation when it is a capsule, it may contain a liquid carrier, such as fatty oil, e.g. cacao butter.
- a liquid carrier such as fatty oil, e.g. cacao butter.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatine, mal, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol water, ethanol and the like.
- the compositions may be solutions, including eye drops, suspensions, ointments, creams, drops, emulsion, tablets, pills, capsules, powders, sustained release formulations and the like.
- the composition may be formulated as a suppository, with traditional binders and carriers such as triglycerides.
- clioquinol and/or phanquinone and the optionally, further active constituents are comprised as separate pharmaceutical entities.
- one entity may comprise vitamin B 12 .
- the two entities may administered simultaneously or sequentially.
- the entity comprising clioquinol and/or phanquinone can be administered, followed by vitamin B 12 administered within a day, week, or month of clioquinol and/or phanquinone administration.
- the entity comprising phanquinone and/or clioquinol is preferably administered for one to three weeks followed by a wash out period of one to four weeks, during which the entity comprising vitamin B 12 is administered but not the entity comprising phanquinone and/or clioquinol. After the wash out period, the treatment may be repeated.
- the pharmaceutical composition may be provided as a pack or kit comprising one or more entities containing one or more of the ingredients of the pharmaceutical compositions of the invention.
- entities containing one or more of the ingredients of the pharmaceutical compositions of the invention.
- associated with such entities may be a notice in the form described by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of the manufacture, use or sale for human administration.
- 250 g phanquinone and 250 g of clioquinol was mixed with 200g of N'-(4'- steatoryl aminophenyl) - trimethylamonium methyl sulphuric acid) and 1025 g lactose mono-hydrate for a period of 5 minutes.
- 300 g of boiling water was added in one go to a mixture of 100 g maize starch in 100 g cold water.
- the maize suspension, cooled to 40° C was added to the phanquinone and clioquinol containing powder mixture under continuous stirring.
- an aqueous solution of 5 g vitamin B 12 was added.
- the mixture was granulated using a 2.5 mm sieve and desiccated for 18 hours at 40° C.
- the dry granules were mixed with
- 250 g phanquinone and 250 g of clioquinol were mixed with 200 g Sapamine (N- (4'- steatoryl aminophenyl) - trimetthylammonium methyl sulphuric acid) and 1025 g lactose mono-hydrate for a period of 5 minutes.
- 300 g of boiling water was added in one go to a mixture of 100 g maize starch in 100 g cold water.
- the maize suspension, cooled to 40°C was added to the phanquinone and clioquinol containing powder mixture under continuous stirring. Subsequently, an aqueous solution of 5 g vitamin B 12 was added.
- Example 3 The mixture was granulated using a 2.5 mm sieve and desiccated for 18 hours at 40°C. The dry granules were mixed with 400 g maize starch and 20 g magnesium stearate. The final mixture was formulated into tablets having a diameter of 8.0 mm and weight of 200 mg.
- Example 3 The mixture was granulated using a 2.5 mm sieve and desiccated for 18 hours at 40°C. The dry granules were mixed with 400 g maize starch and 20 g magnesium stearate. The final mixture was formulated into tablets having a diameter of 8.0 mm and weight of 200 mg.
- Example 3 Example 3
- An ointment for use according to the present invention may be prepared by addition of 1 % clioquinol to a common ointment base comprising Vaseline and white wax.
- Alternative may an ointment be prepared by addition of 0.5 % phanoquinone to an ointment base comprising Vaseline and white wax..
- MMP group MMP group. Specifically, the assay was conducted for MMP-1 , MMP-2, MMP-3, MMP- 7, and MMP-9 at various concentrations.
- the MMP-1 , MMP-3, and MMP-7 were initially pre-incubated in 60 min at 37EC and MMP-2 and MMP-9 were pre-incubated in 60 min at 25EC in an aqueous vehicle of 50 mM MOPS, 10mM CaCI 2 .2H 2 0, 10 ⁇ M ZnCI 2 , 0,05% Brij 35, pH 7.2 and a concentration of clioquinol of 100 ⁇ M.
- a test substrate of Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 was subsequently added to obtain a concentration of 25 ⁇ M.
- MMP-1 was incubated for 2 hours at 37EC
- MMP-2 was incubated for 3 hours at 25EC
- MMP-3 was incubated for 90 min at 37EC
- MMP-7 was incubated for 90 min at 37EC
- MMP-9 was incubated for 2 hours at 25EC.
- the activity of the enzymes was measured by fluorometric quantitation of Mca-Pro-Leu-Gly- OH. The results are indicated in Table I below.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01273136A EP1408969A2 (en) | 2001-01-10 | 2001-11-28 | Use of chelators in the treatment of macular degenerative disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0016369A FR2819187A1 (en) | 2001-01-10 | 2001-01-10 | USE OF CHELATING SUBSTANCES FOR THE TREATMENT AND PREVENTION OF EYE DEFERRESCENCE |
FR00/16369 | 2001-01-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002055081A2 true WO2002055081A2 (en) | 2002-07-18 |
WO2002055081A3 WO2002055081A3 (en) | 2003-11-20 |
Family
ID=8857701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2001/002265 WO2002055081A2 (en) | 2001-01-10 | 2001-11-28 | Use of chelators in the treatment of macular degenerative disease |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1408969A2 (en) |
FR (1) | FR2819187A1 (en) |
WO (1) | WO2002055081A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006117660A2 (en) * | 2005-05-04 | 2006-11-09 | Clio Pharmaceutical Corporation | Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins |
WO2008070579A2 (en) * | 2006-12-01 | 2008-06-12 | Loma Linda University Medical Center | Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
EP2012789A1 (en) * | 2006-04-14 | 2009-01-14 | Prana Biotechnology Limited | Method of treatment of age-related macular degeneration(amd) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2345058A (en) * | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10101566A (en) * | 1996-09-27 | 1998-04-21 | Kagaku Gijutsu Shinko Jigyodan | Medicine for protecting retina |
-
2001
- 2001-01-10 FR FR0016369A patent/FR2819187A1/en not_active Withdrawn
- 2001-11-28 EP EP01273136A patent/EP1408969A2/en not_active Withdrawn
- 2001-11-28 WO PCT/IB2001/002265 patent/WO2002055081A2/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2345058A (en) * | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
Non-Patent Citations (5)
Title |
---|
AHN Y H ET AL: "Depletion of intracellular zinc induces protein synthesis-dependent neuronal apoptosis in mouse cortical culture." EXPERIMENTAL NEUROLOGY. UNITED STATES NOV 1998, vol. 154, no. 1, November 1998 (1998-11), pages 47-56, XP001164155 ISSN: 0014-4886 * |
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 2001 (2001-02) HYUN H J ET AL: "Depletion of intracellular zinc and copper with TPEN results in apoptosis of cultured human retinal pigment epithelial cells." Database accession no. NLM11157883 XP002252417 & INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. UNITED STATES FEB 2001, vol. 42, no. 2, February 2001 (2001-02), pages 460-465, ISSN: 0146-0404 * |
DATABASE WPI Section Ch, Week 199826 Derwent Publications Ltd., London, GB; Class B05, AN 1998-292043 XP002252418 & JP 10 101566 A (KAGAKU GIJUTSU SHINKO JIGYODAN), 21 April 1998 (1998-04-21) * |
HYUN HYAE JUNG ET AL: "Depletion of intracellular zinc induces macromolecule synthesis- and caspase-dependent apoptosis of cultured retinal cells." BRAIN RESEARCH, vol. 869, no. 1-2, 2000, pages 39-48, XP001164156 ISSN: 0006-8993 * |
KAUFFMAN R E ET AL: "CLIOQUINOL IODOCHLORHYDROXYQUIN VIOFORM AND IODOQUINOL DIIODOHYDROXYQUIN BLINDNESS AND NEUROPATHY." PEDIATRICS, (1990) 86 (5), 797-798. , XP008020961 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006117660A2 (en) * | 2005-05-04 | 2006-11-09 | Clio Pharmaceutical Corporation | Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins |
WO2006117660A3 (en) * | 2005-05-04 | 2007-01-04 | Clio Pharmaceutical Corp | Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins |
EP2012789A1 (en) * | 2006-04-14 | 2009-01-14 | Prana Biotechnology Limited | Method of treatment of age-related macular degeneration(amd) |
JP2009533356A (en) * | 2006-04-14 | 2009-09-17 | プラナ バイオテクノロジー リミティッド | Method for treating age-related macular degeneration (AMD) |
EP2012789A4 (en) * | 2006-04-14 | 2011-02-16 | Prana Biotechnology Ltd | Method of treatment of age-related macular degeneration(amd) |
EP2514423A2 (en) | 2006-04-14 | 2012-10-24 | Prana Biotechnology Ltd | Method of treatment of age-related macular degeneration (AMD) |
CN101987849B (en) * | 2006-04-14 | 2013-05-08 | 普拉纳生物技术有限公司 | Method of treatment of age-related macular degeneration(AMD) |
US9163018B2 (en) | 2006-04-14 | 2015-10-20 | Prana Biotechnology Inc. | Method of treatment of age-related macular degeneration (AMD) |
WO2008070579A2 (en) * | 2006-12-01 | 2008-06-12 | Loma Linda University Medical Center | Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
WO2008070579A3 (en) * | 2006-12-01 | 2009-03-19 | Univ Loma Linda Med | Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
Also Published As
Publication number | Publication date |
---|---|
WO2002055081A3 (en) | 2003-11-20 |
EP1408969A2 (en) | 2004-04-21 |
FR2819187A1 (en) | 2002-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sivak | The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease | |
Watson et al. | Scleritis and episcleritis. | |
AU2017201599B2 (en) | APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF | |
JP2009501726A (en) | Ophthalmologically active agent formulations and methods of administration thereof | |
KR20040053181A (en) | Modulation of ocular growth and myopia by GABA drugs | |
US7652070B2 (en) | Treatment method for MMP-implicated pathologies | |
WO2002055081A2 (en) | Use of chelators in the treatment of macular degenerative disease | |
CA3028924A1 (en) | Salbutamol-containing ophthalmic medicament | |
Engler et al. | Interferon alfa-2a modifies the course of subfoveal and juxtafoveal choroidal neovascularisation. | |
KR19980063712A (en) | Lower alkanoyl L-carnitine useful for the treatment of retinopathy | |
WO2008057599A2 (en) | Methods for the treatment of abeta related disorders and compositions therefor | |
CA2871170C (en) | Antibodies or fragments thereof for use in the treatment of ocular diseases. | |
EP2709643B1 (en) | Compositions comprising extracts or materials derived from palm oil vegetation liguor for inhibition of vision loss due to macular degeneration | |
US11717513B2 (en) | Mirabegron for the treatment of retinal diseases | |
JP2003501461A (en) | Neuroprotective and retinoprotective ophthalmic drugs | |
RU2073518C1 (en) | Agent recovering retina eye function | |
JP2008507588A (en) | Methods of treating eye conditions | |
US20210052611A1 (en) | Treatment of lysosomal storage disorders | |
JP2021522283A (en) | Inhibition of lipofuscin aggregation by molecular tweezers | |
KUNDU | Neurologic Wilson’s Disease and its Management-An Update | |
KR20240035456A (en) | Medicines containing glycosidase inhibitors | |
MXPA05005795A (en) | Use of levocetirizine for the treatment of persistent allergic rhinitis. | |
MEDOW | Vision impairment in the pediatric population | |
Musarella | Neurocutaneous syndromes | |
Warfield et al. | Eye Pain: Ocular and Nonocular Causes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001273136 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001273136 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001273136 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |